9688 Panoramica delle azioni Zai Lab Limited sviluppa e commercializza terapie per il trattamento di oncologia, disturbi autoimmuni, malattie infettive e neuroscienze. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Zai Lab Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Zai Lab Prezzi storici delle azioni Prezzo attuale dell'azione US$20.90 Massimo di 52 settimane US$25.80 Minimo di 52 settimane US$10.56 Beta 0.98 Variazione di 1 mese 5.77% Variazione a 3 mesi 30.79% Variazione di 1 anno 5.56% Variazione a 3 anni -59.02% Variazione a 5 anni n/a Variazione dall'IPO -65.74%
Notizie e aggiornamenti recenti
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Zai Lab Limited Announces the Inclusion of Augtyro (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’S National Reimbursement Drug List Nov 28 Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million. Nov 16
Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million. Nov 15
Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China Nov 12
Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China Oct 29 Vedi altri aggiornamenti
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Zai Lab Limited Announces the Inclusion of Augtyro (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’S National Reimbursement Drug List Nov 28 Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million. Nov 16
Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million. Nov 15
Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China Nov 12
Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China Oct 29
Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310 Oct 26
Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024 Oct 16
Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 Oct 09
Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 Sep 18 Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China Jul 16
Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024 Jul 11
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024 Jun 13 Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China May 15
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA May 14
Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024 Apr 16
Zai Lab Limited, Annual General Meeting, Jun 18, 2024 Mar 29
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer Mar 27
Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 19
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors Mar 15
Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024 Jan 26
Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC Jan 11
Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List Dec 13
Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023 Oct 19
Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China Aug 31
Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023 Jul 23 Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Jul 17
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis Jul 12
Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023 Jul 07 Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Jun 07
Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting Jun 02
Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib May 19
Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023 Feb 10
Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration Jan 31 Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors Jan 10
Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint Jan 06
Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development Jan 04
Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary Dec 16
Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer Nov 09
Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022 Oct 19
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting Sep 21
Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer Aug 04
Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022 Jul 20
China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited Jul 14
Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China Jun 11
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Jun 04
Zai Lab Limited, Annual General Meeting, Jun 22, 2022 May 03
Zai Lab Limited to Report Q1, 2022 Results on May 10, 2022 Apr 21
Zai Lab Limited Announces Resignation of Tao Fu, Chief Strategy Officer Apr 03
Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 02, 2022 Feb 18
Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 01, 2022 Feb 16
Zai Lab Limited Announces Treatment of First Patient in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer Jan 13
Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA Jan 07 Zai Lab Limited Announces China NMPA's Approval for NUZYRA® as A Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Zai Lab Announces Inclusion of Zejula® (Niraparib) in China's National Reimbursement Drug List for First-Line Ovarian Cancer Dec 05
Zai Lab Limited Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) Dec 01
Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib May 29
Zai Lab Announces First Patient Treated in Greater China in Metis Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer May 25
Zai Lab Limited Announces Recent Product Highlights and Anticipated Milestones May 11
Zai Lab Limited Appoints Ann Beasley as Chief Compliance Officer Mar 04
Zai Lab Expects to Receive Approval for and Launch QINLOCK and NUZYRA in China Mar 03
Zai Lab Limited to Report Fiscal Year 2020 Results on Mar 01, 2021 Feb 17
Turning Point and Zai Lab Broaden Announces Collaboration Jan 12 Zai Lab Limited Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
Zai Lab Limited Appoints Alan Sandler as President, Head of Global Development, Oncology Dec 02
Zai Lab Limited Announces Dosing of First Patient in China in the Global Pod1um-101 Study Evaluating Retifanlimab in Patients with Previously Treated, Microsatellite Instability-High Endometrial Cancer Oct 30
Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC Oct 06
Zai Lab Limited has completed a Follow-on Equity Offering in the amount of HKD 5.936996 billion. Oct 05 Rendimenti per gli azionisti 9688 HK Biotechs HK Mercato 7D 1.5% -3.9% -0.5% 1Y 5.6% -5.7% 19.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 9688 ha superato il Hong Kong Biotechs che ha restituito -5.7 % nell'ultimo anno.
Rendimento vs Mercato: 9688 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 19.9 % nell'ultimo anno.
Volatilità dei prezzi Is 9688's price volatile compared to industry and market? 9688 volatility 9688 Average Weekly Movement 9.2% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Prezzo delle azioni stabile: 9688 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di 9688 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Zai Lab Limited sviluppa e commercializza terapie per il trattamento di oncologia, disturbi autoimmuni, malattie infettive e neuroscienze. I suoi prodotti commerciali includono Zejula, un inibitore della polimerasi 1/2 somministrato per via orale; Optune, una terapia antitumorale che utilizza campi elettrici sintonizzati su frequenze specifiche per uccidere le cellule tumorali; NUZYRA per le infezioni batteriche acute della pelle e delle strutture cutanee e per la polmonite batterica acquisita in comunità; Qinlock per il trattamento dei tumori stromali gastrointestinali e VYVGART, un frammento di anticorpo IgG1 umano per la miastenia grave. L'azienda sviluppa anche Tumor Treating Fields, un dispositivo portatile per la somministrazione di campi elettrici; Repotrectinib, un inibitore della tirosin-chinasi (TKI) per colpire ROS1 e TRK A/B/C in pazienti oncologici naïve o pretrattati con TKI; Tisotumab vedotin, un coniugato anticorpo-farmaco; Adagrasib per il trattamento del NSCLC mutato in KRAS-G12C, del carcinoma del colon-retto e del carcinoma del pancreas; e Bemarituzumab per il trattamento di pazienti affetti da carcinoma gastrico e della giunzione gastroesofagea.
Mostra di più Zai Lab Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Zai Lab con la sua capitalizzazione di mercato? 9688 statistiche fondamentali Capitalizzazione di mercato HK$22.45b Guadagni(TTM ) -HK$2.10b Ricavi(TTM ) HK$2.76b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 9688 Conto economico (TTM ) Ricavi US$355.75m Costo del fatturato US$395.21m Profitto lordo -US$39.46m Altre spese US$231.39m Guadagni -US$270.85m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -2.50 Margine lordo -11.09% Margine di profitto netto -76.13% Rapporto debito/patrimonio netto 16.9%
Come si è comportato 9688 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/23 12:42 Prezzo dell'azione a fine giornata 2024/12/23 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Zai Lab Limited è coperta da 28 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Michael Meng BOCI Research Ltd. Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd.
Mostra 25 altri analisti 
